Lindbrook Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Lindbrook Capital’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-546	Closed	-$22.3K	–	2939
2024 Q2	$22.3K	Hold	546	–	–	﹤0.01%	1185
2024 Q1	$23.1K	Hold	546	–	–	﹤0.01%	1136
2023 Q4	$23.1K	Buy	546 +456	+507%	+$13.1K	﹤0.01%	1101
2023 Q3	$1.97K	Buy	90 +15	+20%	+$375	﹤0.01%	2135
2023 Q2	$2.38K	Buy	+75	New	+$2.3K	﹤0.01%	2085
2022 Q1	–	Sell	-130	Closed	-$4K	–	2646
2021 Q4	$4K	Buy	130 +80	+160%	+$2.82K	﹤0.01%	1620
2021 Q3	$1K	Buy	+50	New	+$1.4K	﹤0.01%	1816

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Lindbrook Capital's CERE Position: Q3 2024 in Review

Lindbrook Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 546 shares — an estimated $22.3K sold.

Lindbrook Capital first reported a position in CERE in Q3 2021 and held it in 7 quarters. The position peaked at $23.1K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Lindbrook Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Lindbrook Capital sold 546 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $22.3K.
Lindbrook Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Lindbrook Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $23.1K in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.